scPharmaceuticals Inc. (SCPH)
3.46
0.08 (2.37%)
At close: Jan 15, 2025, 2:32 PM
undefined% (undefined)
| Bid | 3.41 |
| Market Cap | 173.14M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.95 |
| PE Ratio (ttm) | -1.77 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.51 |
| Volume | 6,561 |
| Avg. Volume (20D) | 434,188 |
| Open | 3.45 |
| Previous Close | 3.38 |
| Day's Range | 3.45 - 3.46 |
| 52-Week Range | 3.08 - 6.54 |
| Beta | undefined |
About SCPH
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 17, 2017
Employees 135
Stock Exchange NASDAQ
Ticker Symbol SCPH
Analyst Forecast
According to 2 analyst ratings, the average rating for SCPH stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 333.53% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
scPharmaceuticals Inc. is scheduled to release its earnings on Mar 12, 2025,
during market hours.
Analysts project revenue of $12.18M, reflecting a 99.80% YoY growth and earnings per share of -0.39, making a 11.43% increase YoY.
Analysts project revenue of $12.18M, reflecting a 99.80% YoY growth and earnings per share of -0.39, making a 11.43% increase YoY.
1 month ago ·
Source
-5.82%
ScPharmaceuticals shares are trading lower after t...
Unlock content with
Pro Subscription
2 months ago ·
Source
-14.07%
ScPharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 sales results.
